Rays Power Infra announced closure of INR 127 Crore Equity Capital Fund Raise - Rentomojo Limited Announced it's Initial Public Offer (IPO) to open on Wednesday, September 09, 2026 Price Band has been fixed at ₹ 384 to ₹ 404 per Equity Share - Manipal Payment and Identity Solutions Limited Announced its Initial Public Offering (IPO) to Open on Wednesday, September 9, 2026 Price Band fixed at ₹322 to ₹339 per equity share of face value of ₹10 each - LCC Projects fixes IPO price band at Rs 139-146 per share; issue opens on Sep 9 - KARAMTARA ENGINEERING LIMITED ANNOUNCED ITS INITIAL PUBLIC OFFERING (IPO) OF EQUITY SHARES TO OPEN ON WEDNESDAY 09 SEPTEMBER 2026 Price Band fixed at ₹241 to ₹254 per equity share of face value of ₹10 each - LCC Projects Limited announces the price band for its IPO - Ola Electric's First Dealer Stores are Now Open across India - Prasol Chemicals Limited Announced its initial Public Offering (IPO) to Open on September 8 at Price Band of ₹643–₹676 - Asset Reconstruction Company (India) Limited Announced it's Initial Public Offering (IPO) to open on Wednesday, September 09, 2026 The Price Band of the Offer has been fixed from ₹ 132 per Equity Share of face value ₹ 10 each to ₹139per Equity Share of face value of ₹ 10 each - Veegaland Developers Limited’s IPO to Open on Thursday, September 10, 2026 Price Band fixed at ₹130 to ₹140 per equity share of face value of ₹10 each - Veegaland Developers Limited’s IPO to Open on Thursday, September 10, 2026 At the Price Band fixed at ₹130 to ₹140 per equity share of face value of ₹10 each

Kokilaben Dhirubhai Ambani Hospital introduced revolutionary HIFU Technology for Prostate Cancer Treatment

Kokilaben Dhirubhai Ambani Hospital introduced revolutionary HIFU Technology for Prostate Cancer Treatment

Mumbai, December 12, 2023: Kokilaben Dhirubhai Ambani Hospital, Mumbai today announced the introduction of the revolutionary High-Intensity Focused Ultrasound (HIFU) technology, a cutting-edge treatment option for patients with prostate cancer. HIFU is a state-of-the-art treatment that utilizes high-frequency sound waves to target and destroy prostate cancer cells. This minimally invasive technique using focal ablation is a big leap forward in cancer care, offering a targeted approach to treating localized prostate cancer with precision and care.

Dr. Yuvaraja T.B, Head, Robotic Surgery, Consultant, Surgical Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai said, “A non-invasive alternative to traditional cancer treatments, HIFU is ideal for patients with localized prostate cancer. Focal ablation uses extreme temperatures to destroy the cancer tissue focusing on and targeting only the area of the prostate that contains the cancer lesion. This prevents any damage to normal cells in other parts of the prostate gland. HIFU can also be beneficial for patients looking for salvage treatment after previous interventions such as radiation.”

With prostate cancer being one of the top ten leading cancers in India affecting men, integration of HIFU by Kokilaben Hospital for advancing treatments in prostate cancer is an instrumental move. And it will help in providing patients with state-of-the-art, non-invasive treatment options. Under the visionary guidance of its healthcare leaders, the hospital has consistently invested in and adopted the latest advancements in precision oncology. This commitment to innovation ensures that patients diagnosed with prostate cancer will receive the most effective and least invasive treatments available.

HIFU has multiple benefits for patients. As a non-invasive treatment, it significantly reduces the risk of complications associated with conventional surgical procedures. HIFU is performed under general anaesthesia, ensuring patient comfort throughout the procedure. The precision of this technology allows for the preservation of surrounding tissues, resulting in fewer long-term side effects and maintaining patients’ quality of life.

Patients experience minimal pain and discomfort, with a swift return to their daily routines post-treatment. HIFU is also associated with a lower risk of side effects, such as incontinence and impotence, which are often concerns with other treatments for prostate cancer. 

Dr. Santosh Shetty, CEO and Executive Director, Kokilaben Dhirubhai Ambani Hospital, Mumbai said, “Our goal is to help our patients fight cancer with the utmost precision through various modalities minimizing harm to the body while maximizing the efficacy of treatment. HIFU is a game-changer in this regard. It helps us to not only offer one more option for the treatment of cancer, but also enhance our patients’ overall treatment experience. It is a matter of pride that Kokilaben Hospital continues to be a pioneer in providing our patients with the most advanced and effective treatments available,” stated in a press release.ends GNI

Be the first to comment on "Kokilaben Dhirubhai Ambani Hospital introduced revolutionary HIFU Technology for Prostate Cancer Treatment"

Leave a comment

Your email address will not be published.


*